Swiss dermatology group Galderma has agreed to acquire American skincare company ZO Skin Health for an enterprise value of $1.5bn, expanding its position in the market for premium products distributed through medical professionals.
The all-cash transaction will give Galderma 100% ownership of the California-based business, which is being acquired from shareholders including funds managed by Blackstone Tactical Opportunities and the Obagi family.
ZO Skin Health generated approximately $330m in net sales during the 12 months ended June 2026. The business sells more than 40 skincare products through a network of over 16,500 physician, medical spa, and online accounts across more than 40 countries.
The acquisition will strengthen Galderma’s dermatological skincare division, which includes the established Cetaphil and Alastin brands.
Founded by dermatologist Dr Zein Obagi in 2007, ZO Skin Health specialises in skincare regimens supported by professional consultation and product education. Its portfolio includes cleansers, exfoliants, serums, and other products designed for ongoing skincare programmes.
Galderma intends to combine the acquired company’s position in daily skincare with Alastin’s complementary range, which is primarily associated with regenerative skincare and products used around aesthetic procedures.
Both brands are expected to retain their individual identities while benefiting from Galderma’s international commercial infrastructure, scientific expertise, and professional distribution relationships.
The transaction is expected to complete during the fourth quarter of 2026 or early 2027, subject to regulatory approvals and customary closing conditions.
Galderma plans to finance the purchase using existing cash resources and bank funding.
The company expects the acquisition to be broadly neutral to core earnings per share during the first full year after completion.
Additional commercial investment in the acquired business is expected to make the transaction slightly dilutive to Galderma’s core EBITDA margin in 2027. The company expects profitability to approach its group average from 2028.
These projections reflect planned expenditure on marketing, international development, and other measures intended to support the brand’s expansion.
Private equity exit reflects specialist skincare demand
The acquisition represents another significant transaction in the professional skincare market, where companies are expanding portfolios associated with dermatological expertise and established clinical distribution channels.
Unlike mainstream skincare products sold primarily through general retailers, physician-dispensed brands rely heavily on relationships with dermatologists, aesthetic clinics, and other specialist providers.
These relationships can support product education, customer loyalty, and repeat purchases, while requiring investment in professional training, regulatory compliance, and commercial support.
ZO Skin Health’s international network provides Galderma with an established route into this segment, particularly in the United States, where professional aesthetic treatments and associated skincare products represent an important commercial market.
The transaction also marks an exit for Blackstone, which acquired a majority interest in ZO Skin Health in 2020 through its tactical opportunities investment business.
Under Blackstone’s ownership, the company expanded its operations and substantially increased revenue, developing into a larger business with established international distribution.
The sale illustrates how private equity investors can develop specialist consumer healthcare businesses before transferring ownership to strategic buyers seeking complementary products and greater scale.
Galderma’s wider business spans injectable aesthetics, dermatological skincare, and therapeutic dermatology. In 2025, it reported net sales of approximately $5.2bn, with growth across all three divisions.
Adding ZO Skin Health will expand the group’s portfolio without requiring it to establish an entirely new distribution model, although integrating operations and managing different commercial relationships will introduce additional responsibilities.
Maintaining the acquired brand’s identity while expanding its geographic reach will be an important element of the transaction’s execution.
The proposed acquisition remains conditional on completion, with its longer-term financial contribution dependent on the performance of ZO Skin Health and Galderma’s ability to deliver the planned commercial investment.
You must be logged in to post a comment.